NCT00034151已完成2 期
A Phase IIA Evaluation of Safety and Efficacy of Weekly S-8184 Paclitaxel Injectable Emulsion in Second Line Treatment of Stage III or IV Platinum Resistant Ovarian Cancer or Primary Peritoneal Carcinoma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 52
- 主要终点
- Determine the objective and partial response rates
研究概览
简要总结
Phase IIA, multicenter, dose escalation study evaluating the safety and efficacy of weekly S-8184 paclitaxel injectable emulsion in second line treatment of patients with stage III or IV platinum resistant ovarian cancer or primary peritoneal carcinoma.
详细描述
The goals of this study are to determine the objective response rate, to determine time to disease progression, duration of response, and survival, and to identify the maximum tolerated weekly dose and principal toxicities of S-8184 in this patient population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Histologic diagnosis of ovarian cancer or primary peritoneal carcinoma
- •Stage III or IV disease
- •One and only one prior cytotoxic chemotherapy regimen which must have included a platinum agent
- •Platinum resistant disease, defined as documented progression within six months of completion of first line therapy
- •Adult (18 years of age or older) patients
- •Adequate hematologic function (ANC greater than 1500 cells/mm3 and platelets greater than 100,000/mm3)
- •Serum creatinine less than 2.0 mg/dL
- •Total bilirubin less than 1.5 mg/dL; SGOT and SGPT less than 3 times the upper limit of institutional normal values
- •ECOG performance status of 0 - 2
- •Bidimensional measurable or clinically evaluable disease
- •Patients who have signed an IRB / Ethics Committee approved informed consent
- •Life expectancy at least 12 weeks
- •Patient has fully recovered from any previous surgery (at least 4 weeks since major surgery)
- •Patient has a negative pregnancy test prior to study entry if premenopausal. (Patients of child bearing potential must use a medically effective form of contraception during the treatment.)
排除标准
- •Patients who have received any taxane-containing preparation including Taxol (paclitaxel) or Taxotere (docetaxel)
- •Females who are pregnant or lactating
- •Patients with peripheral neuropathy NCI-CTC grade 2 or greater
- •Patients who have received wide-field radiation, cytotoxic chemotherapy or hormonal therapy within 4 weeks of study entry; or mitomycin or nitrosoureas within 6 weeks of study entry
- •Patients who have had an investigational agent within 4 weeks of study entry
- •Patients receiving concurrent anticonvulsants known to induce P450 isoenzymes
结局指标
主要结局
Determine the objective and partial response rates
时间窗: No time frame-based on number of patients
次要结局
- Time to progression, duration of response and duration of survival(Based on number of patients)
研究者
相似试验
已完成
2 期
Safety and Efficacy of S-8184 in Second Line Treatment of Relapsed Stage IIIB or IV Non Small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT00034164Achieve Life Sciences52
已完成
2 期
Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal AdenocarcinomaColorectal AdenocarcinomaNCT00034190Achieve Life Sciences28
已完成
2 期
Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the UrotheliumUrologic NeoplasmsNCT00034177Achieve Life Sciences27
已完成
1 期
Study with S 81694 in perfusion in patients with solid tumorsCancerISRCTN35641359Institut de Recherche Internationales Servier39
已完成
1 期
Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate CancerRising Prostate Specific Antigen (PSA)Prostate CancerNCT02796898Tyme, Inc23